These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
474 related articles for article (PubMed ID: 34237406)
1. Senescent cells in cancer therapy: why and how to remove them. Zhang JW; Zhang D; Yu BP Cancer Lett; 2021 Nov; 520():68-79. PubMed ID: 34237406 [TBL] [Abstract][Full Text] [Related]
2. Senescent Cells in Cancer Therapy: Friends or Foes? Wang B; Kohli J; Demaria M Trends Cancer; 2020 Oct; 6(10):838-857. PubMed ID: 32482536 [TBL] [Abstract][Full Text] [Related]
3. The role of cellular senescence and SASP in tumour microenvironment. Takasugi M; Yoshida Y; Hara E; Ohtani N FEBS J; 2023 Mar; 290(5):1348-1361. PubMed ID: 35106956 [TBL] [Abstract][Full Text] [Related]
4. Senescence of Tumor Cells in Anticancer Therapy-Beneficial and Detrimental Effects. Piskorz WM; Cechowska-Pasko M Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232388 [TBL] [Abstract][Full Text] [Related]
5. Senescence and senolysis in cancer: The latest findings. Imawari Y; Nakanishi M Cancer Sci; 2024 Jul; 115(7):2107-2116. PubMed ID: 38641866 [TBL] [Abstract][Full Text] [Related]
6. Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer. Chambers CR; Ritchie S; Pereira BA; Timpson P Mol Oncol; 2021 Dec; 15(12):3242-3255. PubMed ID: 34137158 [TBL] [Abstract][Full Text] [Related]
7. Senescence in head and neck squamous cell carcinoma: relationship between senescence-associated secretory phenotype (SASP) mRNA expression level and clinicopathological features. Ostrowska K; Niewinski P; Piotrowski I; Ostapowicz J; Koczot S; Suchorska WM; Golusiński P; Masternak MM; Golusiński W Clin Transl Oncol; 2024 Apr; 26(4):1022-1032. PubMed ID: 38175424 [TBL] [Abstract][Full Text] [Related]
8. Senescence and the SASP: many therapeutic avenues. Birch J; Gil J Genes Dev; 2020 Dec; 34(23-24):1565-1576. PubMed ID: 33262144 [TBL] [Abstract][Full Text] [Related]
9. Targeting normal and cancer senescent cells as a strategy of senotherapy. Sikora E; Bielak-Zmijewska A; Mosieniak G Ageing Res Rev; 2019 Nov; 55():100941. PubMed ID: 31408714 [TBL] [Abstract][Full Text] [Related]
10. Pro- and anti-tumorigenic functions of the senescence-associated secretory phenotype. Lau L; David G Expert Opin Ther Targets; 2019 Dec; 23(12):1041-1051. PubMed ID: 30616404 [No Abstract] [Full Text] [Related]
11. The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets. Rossi M; Abdelmohsen K Cells; 2021 Jul; 10(7):. PubMed ID: 34359910 [TBL] [Abstract][Full Text] [Related]
15. The Jekyll and Hyde of Cellular Senescence in Cancer. Demirci D; Dayanc B; Mazi FA; Senturk S Cells; 2021 Jan; 10(2):. PubMed ID: 33494247 [TBL] [Abstract][Full Text] [Related]
16. Senescent cells and their secretory phenotype as targets for cancer therapy. Velarde MC; Demaria M; Campisi J Interdiscip Top Gerontol; 2013; 38():17-27. PubMed ID: 23503512 [TBL] [Abstract][Full Text] [Related]
17. Effects of senescence on the tumour microenvironment and response to therapy. Reynolds LE; Maallin S; Haston S; Martinez-Barbera JP; Hodivala-Dilke KM; Pedrosa AR FEBS J; 2024 Jun; 291(11):2306-2319. PubMed ID: 37873605 [TBL] [Abstract][Full Text] [Related]
18. Potential Regulators of the Senescence-Associated Secretory Phenotype During Senescence and Aging. Han X; Lei Q; Xie J; Liu H; Li J; Zhang X; Zhang T; Gou X J Gerontol A Biol Sci Med Sci; 2022 Nov; 77(11):2207-2218. PubMed ID: 35524726 [TBL] [Abstract][Full Text] [Related]
19. Targeting senescent cells to reshape the tumor microenvironment and improve anticancer efficacy. Jiang B; Zhang W; Zhang X; Sun Y Semin Cancer Biol; 2024 Jun; 101():58-73. PubMed ID: 38810814 [TBL] [Abstract][Full Text] [Related]